Video

Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer

Author(s):

Ursula Matulonis, M.D.
Conference|SGO Annual Meeting on Women's Cancer

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

PARP inhibitors work by blocking the repair of DNA within cancer cells, which then allows other DNA repair molecules to target the broken DNA strand.

Related Videos
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with grey hair.
Image of bald man in suit.
Image of woman with dark hair, smiling.
Image of woman with brown hair.
Image of man with grey hair.
Related Content
Illustration of stomach
February 4th 2025

Neoadjuvant Tyvyt With Chemo Improve Responses in Resectable, Locally Advanced ESCC

Chris Ryan
In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an improvement in response rates.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of man with black hair.
February 3rd 2025

Rybrevant Alone and in Combo With Chemo is Efficacious in HER+ mCRC

Ryan Scott
Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Illustration of intestines.
January 29th 2025

Opdivo Plus Yervoy Improves Outcomes in Metastatic Colorectal Cancer Subset

Russ Conroy
The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.
Kelly Irvin was diagnosed with stage 4 ovarian cancer in January 2016. Catch up on all of Kelly's blogs here!
January 29th 2025

Ovarian Cancer Teaches Hard Life Lessons

Kelly Irvin
Having a life-threatening disease reminds me daily to make the most of whatever time I have.